Clavyst Bio is a biotechnology company that specializes in the development of novel therapeutics for the treatment of diseases with high unmet medical needs. The company leverages its proprietary drug discovery platform to identify and advance small molecule therapeutics.

Clavyst Bio

ClavystBio is a life sciences venture investor set up by Temasek. 
Our mission is to accelerate the commercialization of life sciences breakthroughs into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies in Singapore. We foster partnerships among academics, industry and investors, and convene life sciences communities at our collaborative innovation space Node 1. Together, we advance Singapore as a global life sciences translational hub. 

Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics and digital health companies, as well as early-stage VC funds. 


ClavystBio

Thank you to all our partners and friends, especially those who travelled long distances, for joining us at ClavystBio Connects 2023. We look forward to furthering the great connections and rich conversations that day!

For those who weren't able to join, here's a short video of the day's highlights. Enjoy! 

#collaboratetoinnovate #clavystbio #clavystbioconnects

In the latest episode of ClavystBio Conversations, 65LAB partners Thomas Hanke (Evotec), Christina K. Isacson Ph.D. (Lightstone Ventures), and Shuwen Koh (National University Health System) discuss what it takes to foster #venture creation and build global #biotech companies. 

65LAB is a unique company creation vehicle established by ClavystBio, Evotec, Leaps by Bayer, Lightstone Ventures, Polaris Partners, and the Polaris Innovation Fund to leverage breakthrough science from A*STAR - Agency for Science, Technology and Research, Duke-NUS Medical School and National University of Singapore for #humanhealth impact.

Learn more about 65LAB here: https://65lab.sg/
Watch episode here: https://lnkd.in/ggrN8Qv6


ClavystBio  Senior Associate Ning Mao  shared the stage with Rena Dharmawan  Kevin SW TAN  and Judy Sng  at NUS Yong Loo Lin School of Medicine’ Science Festival in a panel on career paths in #biomedical science.

Moderator Hataitip Tasena, PhD took a poll among the audience of grad students, post docs and undergrads: about 30% were set on pursuing academia, 40% were still on the fence, and 30% were interested in exploring alternative career options.

 At ClavystBio, we see the diverse backgrounds of our team as a strength when it comes to #venturebuilding. Some of us come from academia, others from finance, public sector, arts and the world of start-ups. As Ning, an academic transplant herself, shared: “Keep your options open, network widely and talk to others who have diverged from one path and found fulfilment in another in the biomedical field.”

Thanks to NUS and the excellent fellow panellists for widening perspectives and helping bridge the gap between academia and industry.

Thank you BioCentury Inc. for featuring Sunbird Bio and their novel use of exosomes to tackle #Alzheimers. 

Originating in Prof Huilin Shao's lab at National University of Singapore, Sunbird’s amplified plasmonic exosome (APEX) technology detects extracellular vesicles and the proteins bound to them —potentially revolutionizing early detection and response monitoring in clinical trials. 

“It can detect down to the nanometer size, but most importantly, it’s about 10,000 times more sensitive than currently available blood-based Alzheimer’s diagnostic tests,” said Sunbird Executive Chairman and CEO John McDonough   

Read more here: https://lnkd.in/g8fwatye

#venturebuilding #innovation #diagnostics 
ClavystBio   Polaris Partners  S32 

Thanks Lianhe Zaobao 联合早报 for featuring ClavystBio in this trend overview, highlighting the resilience of Singapore's VC scene amid the challenging macroeconomic climate. 

Industry leaders spoke about the growing interest in early-stage innovations in local companies here, with the most active venture capital deal activity in ASEAN. 

"Local innovation and clinical performance needs to be quickly transformed and commercialized" said ClavystBio CEO Khoo Shih, explaining ClavystBio's mission to provide catalytic capital across the ecosystem to translate outstanding science in Singapore into human health impact. 

Read more: https://lnkd.in/gG_u-Etf

#innovation #entrepreneurship #investments

Metric
Company Name	Clavyst Bio
Symbol
MSH ID	COM:CLAVYSTBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	SG
Stage
Employee Count	16
Website	clavystbio.com
LinkedIn	clavystbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CLAVYSTBIO

Clavyst Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue